Fish oil left blood fats and blood sugar unmoved in diabetes trials

Omega-3 fatty acids, whether the marine EPA and DHA in fish oil or plant-derived forms rich in alpha-linolenic acid, are among the most widely taken supplements, and they are often proposed as add-on therapy in diabetes because of potential effects on lipid metabolism, inflammation, oxidative stress and nerve protection. For people living with diabetes, the practical question is which of those hoped-for benefits actually survives contact with randomised trials. This review set out to pool the trial evidence across blood fats, blood sugar control, inflammatory markers and a measure of small nerve fibre health, and to grade how trustworthy the answers are.

The authors searched major databases including MEDLINE, EMBASE, Scopus, the Cochrane trials register, CINAHL and Web of Science through January 2026 for trials of omega-3 supplementation in people with diabetes. Eleven trials met the criteria for quantitative pooling. Outcomes spanned lipid parameters such as triglycerides and cholesterol, glycaemic markers including glycated haemoglobin and fasting glucose, inflammatory and oxidative stress biomarkers, insulin measures, and corneal nerve branch density, an indicator of small-fibre nerve integrity. Random-effects models were applied throughout, and the certainty of the evidence was formally rated.

The headline is what did not move. Pooled analyses showed no significant effects on triglycerides, LDL or HDL cholesterol, glycated haemoglobin, fasting glucose, or inflammatory and oxidative stress biomarkers, with substantial disagreement between trials on several of those outcomes. Two signals did emerge: fasting insulin and a standard index of insulin resistance were significantly reduced, with the trials agreeing closely, and corneal nerve branch density showed a consistent improvement with no detectable disagreement between studies. The authors rate the overall certainty of the evidence as very low to low and describe the whole set of findings as hypothesis-generating rather than confirmatory.

Omega-3's reputation rests heavily on triglyceride lowering, so a pooled null on blood fats in diabetes complicates the standard pitch, though small samples and inconsistent trials mean absence of evidence here is not proof of absence. The insulin sensitivity and nerve integrity signals point in a newer direction, and the close agreement between trials behind them makes them the most interesting leads in the paper. The authors are explicit that adequately powered trials with longer follow-up are needed before either finding can be treated as established, which leaves the field with promising threads rather than answers.

If you take fish oil expecting it to fix cholesterol, blood sugar or inflammation while living with diabetes, this pooled evidence offers little support for those specific expectations. At the same time, it is a reason to watch the insulin sensitivity and nerve health story, where the trials pointed the same way with unusual consistency. Nothing here settles whether the supplement helps or not; the review's own authors rate the certainty as very low to low, which is the strongest reason to hold every conclusion loosely until larger trials report.